行情

LXRX

LXRX

莱斯康制药
NASDAQ

实时行情|Nasdaq Last Sale

1.880
+0.060
+3.30%
盘后: 1.896 +0.016 +0.87% 17:35 04/09 EDT
开盘
1.820
昨收
1.820
最高
1.915
最低
1.810
成交量
105.58万
成交额
--
52周最高
7.27
52周最低
1.125
市值
2.01亿
市盈率(TTM)
1.816
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测LXRX价格均价为5.10,最高价位10.00,最低价为2.300。

EPS

LXRX 新闻

更多
  • LEXICON PHARMACEUTICALS TO HOST VIRTUAL ANNUAL MEETING OF STOCKHOLDERS ON APRIL 23, 2020
  • GlobeNewswire · 3天前
  • Edited Transcript of LXRX earnings conference call or presentation 12-Mar-20 12:00pm GMT
  • Thomson Reuters StreetEvents · 03/30 09:03
  • Lexicon Pharmaceuticals Moving On From Diabetes And Pivoting Toward Clinical Candidates
  • Seeking Alpha - Article · 03/24 17:20
  • Mylan's COVID-19 Medicine, And Other News: The Good, Bad And Ugly Of Biopharma
  • Seeking Alpha - Article · 03/22 11:20

所属板块

生物技术和医学研究
+1.63%
制药与医学研究
+0.82%

热门股票

代码
价格
涨跌幅

LXRX 简况

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.
展开

微牛提供Lexicon Pharmaceuticals, Inc.(NASDAQ-LXRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的LXRX股票新闻,以帮助您做出投资决策。